Eli Lilly is set to drop CVS Health's drug benefit plan for its own employees, with the change taking effect on January 1. The company will transition its employees' pharmacy benefit coverage to Rightway, a privately held pharmacy benefit manager. The decision is a direct response to CVS's move to exclude Lilly's popular weight-loss drug, Zepbound, from its primary reimbursement list. CVS's pharmacy benefit unit, Caremark, had previously favored Zepbound's main competitor, Wegovy from Novo Nordisk, after reportedly negotiating more favorable pricing for that medication. The move underscores the escalating tensions between pharmaceutical giants and pharmacy benefit managers over the lucrative obesity drug market. While a significant strategic decision, there was no widespread reporting of a direct and significant impact on Lilly's stock price specifically attributed to this announcement.